Metrics as of 10/14/2026, 08:33 PM (Berlin time), refresh in progress.
Theravance Biopharma Stock
Theravance Biopharma Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Rick E. Winningham
- Employees
- 90
- Market cap
- $884 M
- IPO
- 16/05/2014
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily…
Theravance Biopharma stock: price history
1D
+0.0%
1W
+0.1%
1M
+0.0%
6M
+12.9%
YTD
-9.0%
1Y
+23.5%
2Y
+113.9%
5Y
+142.6%
10Y
-52.4%
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~14% stronger price swings than usual
Ask the agents about Theravance Biopharma
Analyst assessment of Theravance Biopharma
PRICE TARGET LOW
US$17.00
CONSENSUS
US$17.00
MEDIAN
US$17.00
PRICE TARGET HIGH
US$17.00
0
STRONG BUY
4
BUY
10
HOLD
3
SELL
0
STRONG SELL
17
TOTAL · Hold
As of: 07/07/2026
Theravance Biopharma stock metrics
P/E
16.01
P/B
3.04
EV/EBITDA
10.24
RETURN ON EQUITY
-2.0%
NET MARGIN
-28.5%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.5%
FLOAT SHARES
48,478,429
AVG. DAILY VOLUME (30D)
885,413
Insider transactions (SEC)
Weiss Asset Management LP
MITCHELL DEAN J
MITCHELL DEAN J
Miller Aine
Grimaud Brett A.
Institutional holders
Comparable stocks
Frequently asked questions about Theravance Biopharma stock
What does Theravance Biopharma do?
Theravance Biopharma Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Rick E. Winningham, the company employs around 90 people.
The IPO was on 16/05/2014; the stock trades on NASDAQ under the ticker TBPH.
What do analysts say about Theravance Biopharma stock?
17 analysts rate the stock, the consensus is Hold (as of 07/07/2026).
The average price target is US$17.00, ranging from US$17.00 to US$17.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does Theravance Biopharma report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 14% stronger than usual.
Does Theravance Biopharma pay a dividend?
No, Theravance Biopharma currently does not pay a dividend.
Which stocks are comparable to Theravance Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Theravance Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Theravance Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.